INTRODUCTION
Type-1 protein phosphatases (PP1s) regulate numerous cellular processes by dephosphorylation of key proteins on specific serine or threonine residues [1] [2] [3] . They consist of a catalytic subunit of PP1 (PP1 C ) and one or two non-catalytic subunits. While mammalian cells contain at most a few isoforms of PP1 C , they may express tens of structurally unrelated non-catalytic subunits [1] [2] [3] [4] . Altogether, about 20 mammalian non-catalytic subunits of PP1 have already been characterized. They are endowed with substrate-specifying and regulatory roles and, in some instances, also mediate the anchoring of the holoenzymes to substrates or to subcellular structures to which the substrates are attached. For example, the G-subunits not only target PP1 C to glycogen particles but also increase its glycogen synthase-phosphatase activity [2] . In addition, the G-subunits mediate the hormonal and metabolic control of the holoenzyme by the binding of allosteric effectors or by the phosphorylation of sites that modulate their interaction with the catalytic subunit. Other regulatory subunits of PP1 seem to fulfil a more restricted role. Thus inhibitor-1 and the structurally related DARPP-32 (dopamine-and cAMP-regulated phosphoprotein of 32 kDa) are inhibitory to PP1 C , but only after phosphorylation by protein kinase A (PKA), and they have no known anchoring function [1] [2] [3] 5] .
A detailed understanding of how the regulatory subunits modulate the activity and substrate specificity of PP1 C requires an insight into the molecular determinants of their interaction. Nearly all regulatory subunits appear to have a short motif, often conforming to the sequence RVXF [6, 7] , which binds in a hydrophobic channel near the C-terminus of the catalytic subunit Abbreviations used : EGFP, enhanced green fluorescent protein ; MBP, myelin basic protein ; PP1, protein phosphatase-1 ; NIPP1, nuclear inhibitor of PP1 ; PKA, protein kinase A ; PP1 C , catalytic subunit of PP1 ; PP1N NIPP1 , complex of PP1 C and NIPP1 ; DARPP-32, dopamine-and cAMP-regulated phosphoprotein of 32 kDa. 1 To whom correspondence should be addressed (e-mail Mathieu.Bollen!med.kuleuven.ac.be).
of either domain completely abolished the ability of NIPP1 to inhibit the dephosphorylation of myelin basic protein. The inhibitory potency of the C-terminal site of NIPP1 was decreased by phosphorylation of Tyr-335 and by the addition of RNA. Tyr-335 could be phosphorylated by tyrosine kinase Lyn, but only in the presence of RNA. In conclusion, NIPP1 contains two phosphatase-binding domains that function co-operatively but which are controlled independently. Our data are in agreement with a shared-site model for the interaction of PP1 C with its regulatory subunits.
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[6]. On the other hand, it has been established that the β12-β13 loop near the active site of the catalytic subunit is essential for inhibition by various toxins and protein inhibitors [8] . While common or overlapping binding sites may explain why PP1 C does not interact directly with more than one regulator simultaneously, they do not account for the functional differences between the regulatory subunits. An emerging picture is that these differences stem from multiple sites of interaction between the regulatory and catalytic subunits. Thus inhibitor-1 and DARPP-32 contain, besides an RVXF-like sequence, a motif that inhibits the catalytic subunit by acting as a pseudosubstrate after phosphorylation by PKA [9] . Likewise, inhibitor-2 contains several sites of interaction with PP1 C , in addition to a sequence that may be equivalent to the RVXF sequence [9] [10] [11] . Nuclear inhibitor of PP1 (NIPP1 ; 39 kDa) forms an inactive complex with PP1 C , termed PP1N NIPP" [12, 13] . The holoenzyme can be activated by phosphorylation of up to four Ser\Thr residues in the central domain of NIPP1 by PKA and protein kinase CK2 [14] [15] [16] . This activation results from a disruption of the interaction between PP1 C and the RVXF sequence (residues 200-203) of NIPP1, and from a reduced inhibitory potency of an upstream polybasic inhibitory site (residues 191-200) [17] . Besides interacting with PP1 C , NIPP1 can also bind to RNA, preferentially A\U-rich sequences, via a lysine-rich motif in the Cterminal region [18, 19] . Since the binding of PP1 C and RNA are not mutually exclusive, it has been proposed that NIPP1 may function as an RNA-targeting subunit of PP1 [18] . The Nterminus of NIPP1 consists largely of a ' forkhead-associated ' protein-interaction domain that interacts with CDC5L, a regulator of pre-mRNA splicing and mitotic entry [20] . The association of NIPP1 with splicing factor(s) and\or RNA may account for the localization of PP1N NIPP" in the nuclear speckles [21] , which largely correspond to the interchromatin granule clusters [21] .
A fragment encompassing the central domain of NIPP1 (residues 143-217) was found to be an equally potent inhibitor as the full-length protein [17] . However, two lines of indirect evidence pointed to the existence of additional phosphatasebinding site(s) in the N-and\or C-terminal thirds of NIPP1. First, activation of PP1N NIPP" by phosphorylation of NIPP1 [16] or by competition with the synthetic peptide NIPP1"*"
-#"! [17] , which includes the polybasic and RVXF-binding sites for PP1 C , required the presence of salt. On the other hand, no salt was required for the activation of a complex with NIPP1"%$ -#"(. Second, while phosphorylation or the addition of NIPP1"*"
-#"! resulted in a disruption of the complex between PP1 C and NIPP1"%$ -#"(, no dissociation was seen when the complex had been made with full-length NIPP1 [16, 17] . In further agreement with the existence of additional phosphatase-interaction site(s), we report here that mutation of the PP1 C -binding sites in the central domain of NIPP1 did not abolish its interaction with the catalytic subunit. Using various independent approaches, we have mapped an additional phosphatase-binding site to the C-terminus of NIPP1. Depending on the substrate used, the central and C-terminal binding sites acted independently or synergistically in the inhibition of PP1 C . We also show that the inhibitory potency of the C-terminal site is decreased by the binding of RNA and by phosphorylation of Tyr-335.
EXPERIMENTAL
The preparation of polyhistidine-tagged NIPP1##& -$&", NIPP1##& -$"! and NIPP1$"" -$&" has already been described [19] . The cDNAs encoding NIPP1" -"%#, NIPP1"%$ -##%, NIPP1" -$#* and NIPP1" The inhibition of the phosphorylase phosphatase activity of PP1 C by the indicated concentrations of wild-type and mutated NIPP1 143-224 and NIPP1 , expressed as meanspS.E.M. of four assays.
(NIPP1" -"%#) or XhoI-XhoI (NIPP1" -$&") restriction sites, for expression in BL21(DE3)pLysS cells as polyhistidine-tagged polypeptides. The latter proteins were purified on Ni# + -pentadentate-chelator-Sepharose columns (Affiland). Constructs encoding NIPP1" -$&" or NIPP1" -$#& that were fused C-terminally to the enhanced green fluorescent protein (EGFP), for expression in COS-1 cells, were made by cloning of the bovine NIPP1 cDNAs into the XhoI-SacII sites of pEGFP-N1 (Clontech). All other NIPP1 fragments and phosphopeptides were made synthetically on a Milligen 9050 (Applied Biosystems), using the N-(9-fluorenyl)methoxycarbonyl method. Mutations of the RVTF and polybasic sequences in the central domain of NIPP1 (see Figure 1A ) and of C-terminal phosphorylation sites were made according to the QuikChange site-directed mutagenesis protocol of Stratagene, using the appropriate primers and templates. The sequences of the DNA constructs were verified by cycle sequencing on an AlfII sequencer (Amersham Pharmacia Biotech).
The indicated polyhistidine-tagged NIPP1 fragments (250 pmol) were applied to a column of 0.2 ml of Ni# + -Sepharose, equilibrated in a buffer containing 50 mM Tris\HCl, pH 7.4, 5 mM imidazole, 0.5 mM benzamidine, 0.5 mM PMSF and 50 mM NaCl. Subsequently, 120 pmol of rabbit muscle PP1 C in equilibration buffer plus BSA (0.2 mg\ml) was applied to the columns. The retained catalytic subunit was eluted as a complex with the tagged NIPP1 fragment by elution with equilibration buffer supplemented with 0.4 M imidazole. The distribution of the catalytic subunit between the flow-through and eluate fractions was calculated from the trypsin-revealed phosphorylase phosphatase activity [22] .
COS-1 cells were grown in Dulbecco's modified Eagle's medium containing 10 % fetal calf serum. The cells were transfected using the FuGene4 6 reagent (Roche Diagnostics). After transfection (36 h) the cells were washed twice with ice-cold PBS and lysed in 20 mM Tris\HCl, pH 7.5, 0.5 mM dithiothreitol, 0.2 % Triton X-100, 0.3 M NaCl, 0.5 mM PMSF, 0.5 mM benzamidine and 5 µM leupeptin. Following centrifugation (5 min at 5000 g) the cell lysates were used for the immunoprecipitation of the NIPP1-EGFP fusion proteins with EGFP antibodies and Protein A-TSK-Sepharose TM (Affiland). The immunoprecipitates were washed twice with Tris-buffered saline, resuspended in 20 mM glycylglycine, pH 7.4\1 mg\ml BSA, and used for the assay of the trypsin-revealed phosphorylase phosphatase activity and for Western-blot analysis with EGFP antibodies.
Unless indicated otherwise the protein phosphatase activities were measured with 4 nM catalytic subunit, and either phosphorylase a or myelin basic protein (MBP) as substrate [1] . The tyrosine kinase Lyn was purified from rat spleen as described in [23] . Phosphorylation reactions with the kinase Lyn were performed in 20 mM glycylglycine, pH 7.4, 0.5 mM dithiothreitol, 0.5 mM ATP, 2 mM MgCl # , 2 mM MnCl # , 1 mM CaCl # and the indicated concentrations of poly(U) RNA. The tyrosine phosphorylation was assessed from Western-blot analysis with phosphotyrosine antibodies (Santa Cruz Biotechnology). All other materials and protocols were essentially as described by Beullens et al. [17, 22] .
RESULTS

Mapping of a novel PP1 C -binding site to the C-terminus of NIPP1
Alanine mutation of either the polybasic or the RVTF-interaction sites for PP1 C ( Figure 1A ) decreased the inhibitory potency of the central domain of NIPP1 (NIPP1"%$ -##%) by two to three orders of magnitude ( Figure 1B ). The combined mutations were even more Interaction of protein phosphatase-1 (PP1) with nuclear inhibitor of PP1
Figure 2 Mapping of an inhibitory PP1 C -binding site to the C-terminus of NIPP1
Shown are the concentrations of the indicated NIPP1 fragments (meanspS.E.M. from four experiments) that inhibited the phosphorylase phosphatase activity of 4 nM PP1 C by 50 % (IC 50 ).
deleterious, resulting in an IC &! of 11 µM as compared with only 0.3 nM for the wild type. The pA plus RATA mutations (see Figure 1A ) also abolished the binding of digoxigenin-labelled PP1 C to NIPP1"%$ -##% in an overlay assay (results not shown). Thus the polybasic and RVTF sequences form essential sites for the binding and inhibition of PP1 C by NIPP1"%$ -##%. By contrast, the pA-RATA mutations only moderately increased the IC &! of full-length NIPP1, from 1.8 to 60 nM ( Figure 1B ). The pA-RATA mutant of NIPP1" -$&" also retained some affinity for digoxigenin-labelled PP1 C in a far-Western assay (results not shown).
Paradoxically, with phosphorylase as substrate the central domain of NIPP1"%$ -##% inhibited PP1 C with an IC &! value (0.27 nM) even lower than that of intact NIPP1 (1.8 nM) and lower than expected for a stoichiometric inhibitor, i.e. 2 nM at 4 nM PP1 C (Figures 1 and 2 ). This sub-stoichiometric inhibition could indicate that the purified PP1 C from skeletal muscle was actually a mixture of an active and an inactive pool, which would both bind intact NIPP1, while NIPP1"%$ -##% would only bind to the active pool of catalytic subunit. In support of this interpretation are observations that purified PP1 C is converted gradually into an inactive, metal-dependent, form during storage, which displays a severely decreased sensitivity to inhibitor-1 [24] .
The above data ( Figure 1 ) reinforced earlier indications for the existence of additional inhibitory binding site(s) for PP1 C in the N-or C-terminal thirds of NIPP1 (see the Introduction). Assays of recombinant NIPP1 fragments indeed revealed that, besides the central domain, the C-terminal third of NIPP1 (residues 225-351) was also inhibitory to the phosphorylase phosphatase activity of PP1 C , with an IC &! of 380 nM ( Figure 2 ). Moreover, NIPP1##&
-$&" also interacted with digoxigenin-PP1 C in an overlay assay (results not shown). Analysis of smaller C-terminal fragments showed that the full inhibitory power was retained in residues 311-351 (Figure 2 ). An N-terminally truncated peptide, NIPP1$$! -$&", showed a 10-fold higher IC &! value (3.3 µM). A further 16-fold increase in the IC &! (53 µM) was noted for NIPP1$$" -$$(, which consists of the sequence KKKK- YAK and is reminiscent of the polybasic inhibitory site in the central domain. Thus residues 331-337 appear to represent the core inhibitory sequence, but the N-and C-terminally flanking sequences, which are not inhibitory by themselves (Figure 2 ), are required for the high-affinity binding to PP1 C . Figure 2 also shows that deletion of the C-terminal inhibitory region (residues 330-351) in intact NIPP1 decreased its IC &! from 1.8 nM to the sub-stoichiometric value of 0.4 nM. This indicates that it is the C-terminal region which binds to both inactive and active PP1 C (see above).
Relative importance of the PP1 C -binding sites
To delineate the extent to which the central and C-terminal domains of NIPP1 contribute to the binding of PP1 C , we have generated NIPP1 variants that are mutated in either one or both phosphatase-binding sites. Mutation of either the central sites (pA-RATA mutation) or deletion of the C-terminal site (residues 330-351) merely decreased the binding of the catalytic subunit to the corresponding NIPP1-Sepharose, whereas the combined mutation and deletion prevented the binding of PP1 C (Table 1) . We also expressed wild-type and mutant NIPP1 as fusion proteins with EGFP in COS-1 cells. NIPP1-EGFP could be immunoprecipitated from the cell lysates as a complex with PP1 C , as shown by the trypsin-revealed phosphorylase phosphatase activity (Table 1) . However, both the pA-RATA mutation and the deletion of the C-terminal binding site were required to abolish the co-immunoprecipitation with PP1 C .
While the above data indicate strongly that both the central and C-terminal domains of NIPP1 are required for an efficient binding of the catalytic subunit, they do not reveal the contribution of these domains to the inhibition of PP1 C . Actually, the C-terminal domain might contribute little to the inhibitory potency of NIPP1, since the central domain is at least as potent an inhibitor of the phosphorylase phosphatase activity as is fulllength NIPP1 (Figure 2 ). However, since the inhibition by some regulators of PP1 is substrate-dependent [12] , we have explored whether this perhaps also applies to the central and C-terminal domains of NIPP1. Figure 3 compares the effects of NIPP1 fragments and mutants on the dephosphorylation of phosphorylase a and of MBP by PP1 C . Interestingly, while full-length NIPP1 ( Figure 3A ) and NIPP1##& -$&" ( Figure 3B ) were equally inhibitory to the dephosphorylation of phosphorylase and MBP, NIPP1"%$ -##% only inhibited the dephosphorylation of phosphorylase ( Figure 3C ). Furthermore, mutation in intact NIPP1 of either the central or the C-terminal PP1 C -binding sites altered the inhibitory potency to that of the remaining intact site when phosphorylase was used as a substrate (Figures 3D and 3E) . However, either mutation abolished the inhibition of the MBP dephosphorylation. Finally, mutation of both the central and Cterminal binding sites almost completely abolished the inhibitory potency towards the dephosphorylation of phosphorylase ( Figure  3F ). The latter mutations even converted NIPP1 into a mild activator of the MBP phosphatase activity of PP1 C (Figure 3F ), as was also observed with NIPP1"%$ -##% ( Figure 3C ). Thus both inhibitory sites appear to act independently with phosphorylase as a substrate, but synergistically with MBP as a substrate. -$#*-Sepharose or pA-RATA-mutated NIPP1-Sepharose, respectively (results not shown). As to the phosphorylase phosphatase activity of PP1 C , we have shown that NIPP1"*" -#"! antagonized the inhibitory effects of NIPP1"%$ -##% as well as that of inhibitor-1 and inhibitor-2 [17] . In contrast, NIPP1$$! -$&" opposed only the inhibitory effect of inhibitor-2 ( Figure 4) , and not those of NIPP1"%$ -##% and of inhibitor-1 (results not shown). Overall, these data suggest that the central and C-terminal sites of NIPP1 interact with different fragments of the catalytic subunit and that the C-terminal binding site in NIPP1 is equivalent to a phosphatase-interaction site in inhibitor-2. Interaction of protein phosphatase-1 (PP1) with nuclear inhibitor of PP1 .
Figure 5 Effect of ionic strength on the inhibition of PP1 C by NIPP1 fragments
The Figure 
Regulation of the C-terminal site by ionic strength and RNA binding
The existence of an additional C-terminal interaction site has prompted us to reconsider some earlier observations [17] . We had noted that the phosphorylase phosphatase activity of the inactive complex between PP1 C and intact NIPP1 could be restored by phosphorylation or by competition with NIPP1"*" -#"!, but only in the presence of salt, whereas no salt was required for the activation of a complex with NIPP1"%$ These data suggested that the PP1-binding site in the C-terminus could be sensitive to the ionic strength. In accordance with this interpretation we found that the IC &! of NIPP1##& -$&" was increased to the micromolar range by the addition of 150 mM NaCl, while the inhibitory potency of NIPP1"%$ -##% was barely affected by the ionic strength ( Figure 5) . Likewise, the inhibitory potency of full-length NIPP1 became dramatically dependent on the ionic strength after mutation of the central binding sites. By contrast, the C-terminally deleted NIPP1" -$#* was not saltsensitive.
The C-terminal phosphatase-interaction site was mapped to the same NIPP1 fragment that also contains the lysine-rich RNA-binding motif [19] . In Figure 6 it is shown that the addition of RNA nearly abolished the inhibitory effect of NIPP1##& 
Effects of phosphorylations in the C-terminus
The interaction between PP1 C and the central domain of NIPP1 is weakened by phosphorylation with PKA and protein kinase CK2 [14] [15] [16] . We wondered whether the interaction with the Cterminal inhibition site was also affected by phosphorylation. For that purpose we prepared NIPP1$$! -$&" with its three Ser\ Thr\Tyr residues variously phosphorylated. In Figure 7 (A) it is shown that phosphorylation of Tyr-335 decreased the inhibitory potency of the peptide on the phosphorylase phosphatase activity about 10-fold, whereas the phosphorylation of Ser-348 or Thr-346 had little or no effect. However, the triple-phosphorylated peptide was clearly less inhibitory than the Tyr-335-phosphorylated peptide. We also found that the Tyr-335 to Asp mutation in NIPP1##& -$&" mimicked the effect of phosphorylation, in that it increased the IC &! from 115p32 nM to 2267p370 nM ( Figure 7B ). By contrast, the Ser-348 to Asp or Thr-346 to Asp mutations had no clear effect on the inhibitory potency of NIPP1##& -$&". We also found that the Tyr-335 to Asp mutation abolished the binding of digoxigenin-labelled PP1 C to NIPP1##& -$&" in an overlay assay ( Figure 7B, inset) . Furthermore, the pA-RATA mutant of NIPP1" -$&"-EGFP from COS-1 cell lysates, which still co-immunoprecipitated with PP1 C (Table 1) , no longer did so following the Tyr-335 to Asp mutation (results not shown). On the other hand, a Ni# + -Sepharose column that was saturated with the Tyr-335 to Asp mutant of NIPP1##& -$&" was still able to bind some PP1 C (results not shown). Collectively, these data suggest that the Tyr-335 to Asp mutation severely decreases, but does not entirely abolish, the affinity of NIPP1##& -$&" for PP1 C . The dephosphorylation of MBP by PP1 C was only inhibited by low concentrations of full-length NIPP1 when the phosphatasebinding sites in both the central and C-terminal domains were intact (Figure 3 ). Since the Tyr-335 to Asp mutation decreased the inhibitory potency of the C-terminal domain ( Figure 7B ), we speculated that this mutation would also decrease the inhibitory potency of full-length NIPP1 towards the dephosphorylation of MBP. In Figure 8 it is shown that the Tyr-335 to Asp mutant was indeed a much less potent inhibitor of the MBP phosphatase activity. By contrast, the dephosphorylation of phosphorylase was not affected by this mutation, in keeping with the observation that the inhibition of the phosphorylase phosphatase activity by NIPP1 is largely mediated by its central domain (Figure 3) . We have also explored whether Tyr-335 of NIPP1 is a substrate for tyrosine protein kinases. We found that NIPP1##& -$&" is a substrate for tyrosine phosphorylation by Lyn, a member of the Src kinase family (Figure 9 ). However, further analysis using recombinant and synthetic NIPP1 fragments showed that this phosphorylation involved Tyr-264. Thus the tyrosine phosphorylation of NIPP1##& -$&" by Lyn was abolished by the Tyr-264 to Asp mutation. We found, however, that the Tyr-264 to Asp mutant of NIPP1##& -$&" could be tyrosine-phosphorylated by Lyn in the presence of poly(U). The latter phosphorylation was abolished by the Tyr-335 to Asp mutation. Thus these data indicate that Lyn phosphorylates both Tyr-264 and Tyr-335, but that the phosphorylation of Tyr-335 is dependent on the association of NIPP1##& 
DISCUSSION
Diversity of PP1 C -interaction sites in NIPP1
The present results confirm and extend our previous findings on the existence of two PP1 C -binding sites in the central domain of NIPP1 [17] . While studies with synthetic peptides suggested that the RVTF motif as such was not inhibitory [17] , we report here that mutation of this motif decreased the inhibitory potency of the central domain of NIPP1 by more than 1000-fold ( Figure  1B ). Thus the RVTF sequence, although not inhibitory as such, may be required for an efficient inhibition by the polybasic site. This view accounts also for observations that PP1N NIPP" is activated by disruption of the RVTF-mediated interaction site by phosphorylation of its flanking Ser residues [16, 17] . We have mapped a distinct interaction domain for PP1 C to the C-terminal site of NIPP1 (Figure 2) . Following mutation of the phosphatasebinding sites in both the central and C-terminal domains, NIPP1 was no longer able to bind and inhibit PP1 C (Table 1 and Figure  3F ). This suggests that NIPP1 does not contain other sites that by themselves are sufficient to bind the catalytic subunit, but it does not rule out the possibility that NIPP1 contains additional sites that modulate the interaction with PP1 C .
The binding of PP1 C to the C-terminus of NIPP1 accounts for our failure to disrupt a complex between PP1 C and full-length NIPP1 under conditions (phosphorylation of NIPP1 by PKA plus protein kinase CK2 or competition with NIPP1"*"
-#"!) that disrupted a complex with NIPP1"%$ -#"( [17] . Likewise, the salt requirement for the activation of PP1N NIPP" [16, 17] can be explained by the sensitivity of the C-terminal site to ionic strength ( Figure 5 ). Finally, the requirement of both the central and the C-terminal sites for NIPP1 to inhibit the dephosphorylation of MBP by PP1 C (Figure 3) clarifies why a proteolytic fragment of NIPP1, roughly corresponding to the central domain of NIPP1, was only a poor inhibitor of MBP dephosphorylation [12] .
Regulation of the NIPP1-PP1 C interaction
While the central PP1 C -binding domain of NIPP1 is controlled by Ser\Thr phosphorylation [16, 17] , the C-terminal interaction site was found to be modulated by tyrosine phosphorylation (Figures 7-9) , by the binding of RNA ( Figure 6 ) and by ionic strength ( Figure 5 ). Thus far we have not yet been able to demonstrate that NIPP1, when expressed as a fusion protein with EGFP in COS-1 cells, is phosphorylated on tyrosine. However, this is not really surprising, since the phosphorylation of Tyr-335 appears to be RNA-dependent ( Figure 9 ) and we do not yet know what determines the association of NIPP1 with RNA in i o. It is also possible that the phosphorylation of NIPP1 on Tyr-335 in i o is very transient (e.g. during premRNA splicing) and\or involves only a minor portion of NIPP1.
We previously speculated that NIPP1 acts as an RNA-targeting subunit of PP1, since it can bind simultaneously to PP1 C [13] . Our present observations that the binding of RNA directly modulates the activity of PP1N NIPP" (Figure 6 ) and promotes the phosphorylation of NIPP1 on Tyr-335 ( Figure 9 ) are also in agreement with a role of RNA as an allosteric effector. Such a role would make sense, since PP1N NIPP" is presumed to be involved in the regulation of pre-mRNA processing [18, 21] . Moreover, our recent data suggest that the subnuclear targeting of NIPP1 may be assured by the forkhead-associated domain in the N-terminus, which associates with the splicing factor CDC5L [20] .
Competition experiments with NIPP1$$! -$&" suggested that the C-terminal domain of NIPP1 binds to a site on the catalytic subunit that is different from the RVXF-binding site, but which is similar to a binding site for inhibitor-2 ( Figure 4) . Interestingly, it has been demonstrated recently that inhibitor-2, besides an RVXF-like motif, also contains an N-terminal IKGI It is proposed that PP1 C contains only a limited number of interaction sites for its regulatory subunits (PP1 R ), and that the latter share binding sites. The diversity and specificity in the effects of the regulators is achieved by their interaction with a unique set of PP1 C -binding sites. In addition, some R-subunits may contain targeting domains (hatched segments) that anchor the catalytic subunit in close proximity to specific substrates.
phosphatase-binding site [9] . We speculate that the IKGI site of inhibitor-2 and the C-terminal site of NIPP1 bind to the same domain or overlapping domains in PP1 C .
A shared-site model for the interaction of regulatory subunits with PP1 C
For a profound insight into PP1-mediated regulation of cellular processes it is essential to understand why so many different regulatory proteins can interact with the same catalytic subunit, and yet each have a specific effect on its activity and substrate specificity. Given its relatively small size, it seems likely that the catalytic subunit only has a limited number of binding sites for its regulators. They include the RVXF-binding site and the β12-β13 loop in the C-terminal region of the catalytic subunit [6] [7] [8] , the catalytic site that binds the pseudosubstrate domain of inhibitor-1 and DARPP-32 [9] , and a putative site that interacts with the N-terminus of inhibitor-2 and the C-terminus of NIPP1 ( [9] and this study). Work from various groups indicates that most regulatory subunits have multiple sites of interaction with the catalytic subunit and that they can share several binding sites [5, 8, 11, 17] . We suggest that the binding to specific combinations of sites on the catalytic subunit may account for the specific effects of the regulators on its activity and substrate specificity ( Figure 10 ). A simple calculation shows that, with only five binding sites for the regulatory subunits, these could theoretically interact in 31 different ways with the catalytic subunit if the number of interactions varies between 1 and 5. This model may also provide a basis for understanding some types of hormonal and metabolic regulation of PP1 holoenzymes, which may simply involve a control on the number and identity of interaction sites between its subunits. Examples of regulation of this type are the disruption of the RVXF-mediated interaction of NIPP1 and of the muscle G-subunit with PP1 C by phosphorylation [2, 17] and the binding of a fragment of inhibitor-1 and DARPP-32 as a pseudosubstrate to the catalytic site following phosphorylation [9] . An additional level of regulation of the PP1 holoenzymes may be provided by the anchoring of the regulatory subunits to specific substrates or subcellular structures (Figure 10 
